CXCL3 is a Potential Target for Breast Cancer Metastasis

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)

Volume 17, 9 Issues, 2017

Download PDF Flyer

Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.707
5 - Year: 3.446

CXCL3 is a Potential Target for Breast Cancer Metastasis

Current Cancer Drug Targets, 14(3): 294-309.

Author(s): Amanda Lay Pin See, Poh Kuan Chong, Ssu-Yi Lu and Yoon Pin Lim.

Affiliation: Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, MD6, Centre for Translational Medicine #10-01M, 14 Medical Drive, Singapore 117599.


Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.


Breast cancer, chemokine, CXCL3, migration, proteomics, secretome.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 3
First Page: 294
Last Page: 309
Page Count: 16
DOI: 10.2174/1568009614666140305222328
Price: $58
Orphan Drugs and Rare Diseases Europe 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science